Editas Medicine (NASDAQ:EDIT) 報告季度每股虧損$0.55，低於分析師普遍預期的$0.38，相差44.74%。與去年同期每股虧損$0.23相比，這是一個139.13%的下降。公司報告季度銷售額爲$30.604百萬，低於分析師普遍預期的$32.230百萬，相差5.04%。與去年同期的$60.050百萬相比，這是一個49.04%的下降。
以上內容來自Benzinga Earnings專欄，原文如下：
Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.38) by 44.74 percent. This is a 139.13 percent decrease over losses of $(0.23) per share from the same period last year. The company reported quarterly sales of $30.604 million which missed the analyst consensus estimate of $32.230 million by 5.04 percent. This is a 49.04 percent decrease over sales of $60.050 million the same period last year.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。